Evolving the Treatment Paradigm In Second-Line Primary Biliary Cholangitis With IQIRVO? (elafibranor): A First-in-Class PPAR Agonist Primary biliary cholangitis (PBC; formerly primary biliary cirrhosis) is a chronic, cholestatic liver dis.ease stemming from autoimmune destruction of small bile ducts.1-3 The pooled global incidence is 14.60 per INDICATION IQIRVO? is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an
APRIL 1, 2025